Skip to main content
. Author manuscript; available in PMC: 2020 Feb 1.
Published in final edited form as: Neurochem Int. 2018 May 22;123:59–68. doi: 10.1016/j.neuint.2018.05.013

Figure 4. Azaperone does not rescue DA-independent paralysis induced by treatments of N2 with βPEA or aldicarb, or by unc-49 mutant.

Figure 4

A) Azaperone (250μM) fails to suppress paralysis of N2 animals treated with aldicarb (1mM, 30 min) compared to aldicarb-treated N2. N ≥ 200. B) Azaperone fails to reverse paralysis of N2 animals treated with aldicarb. Both vehicle-incubated N2 and aldicarb-incubated N2 were treated with azaperone (250μM) or azaperone vehicle 30 min after initiation of swimming assay. N= 240 for both groups. C) Azaperone (250μM) fails to suppress paralysis of N2 animals treated with βPEA (1 mM, 10 min) compared to βPEA-treated N2. N for all groups = 240. D) Azaperone fails to reverse paralysis of N2 animals treated with βPEA. Both vehicle-incubated N2 and βPEA-incubated N2 were treated with azaperone (250μM) or azaperone vehicle 30 min after initiation of swimming assay. N= 160 for both groups. E) Azaperone (250μM) fails to suppress paralysis of unc-49(e407) animals compared to unc-49(e407) animals treated with vehicle. N for all groups = 240. F) Azaperone fails to reverse paralysis of unc-49(e407) animals. (unc-49(e407) animals were treated with azaperone (250μM) or vehicle 30 min after initiation of swimming assay. N= 160 for both groups. Data in A, C and E were analyzed using a one-way ANOVA, with selected Bonferroni’s multiple comparisons tests, comparing N2 with azaperone to other groups. Data in B, D, and F were analyzed by a two-way, repeated-measures ANOVA with selected Bonferroni’s comparisons between azaperone and control at each time point. (**** = P value < 0.0001, ns = nonsignificant, P > 0.05).